Autologous Regulatory Т-cell Therapy

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameAutologous Regulatory Т-cell Therapy

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TregsCell and gene therapy > Cell therapy > Source of cells > PMBC-derived

Mechanisms of ActionT-cell surface antigen CD4 modulators

TargetsT-cell surface antigen CD4

Therapy Area/IndicationsScleroderma, Systemic

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelarus

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesInstitute Of Biophysics And Cell Engineering Of National Academy Of Sciences Of Belarus

China Registration ClassN/A

Develop Information

Active CompaniesInstitute Of Biophysics And Cell Engineering Of National Academy Of Sciences Of Belarus

Inactive CompaniesN/A

Active IndicationsScleroderma, Systemic

Inactive IndicationsN/A

Other Information

ATC CodeN/A